Cyclin K

Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers

Retrieved on: 
Thursday, February 25, 2021
Branches of biology, Biology, Transcription factors, Cell Cycle, Myc, Oncogenes, Proteins, Cyclin-dependent kinase 9, Androgen receptor, Cyclin K, Cyclin T1

Scientific research has established that MYC requires CDK9 to drive its own expression and to drive expression of its target genes.

Key Points: 
  • Scientific research has established that MYC requires CDK9 to drive its own expression and to drive expression of its target genes.
  • The open-label, multi-center Phase 1/2 clinical trial of KB-0742 is expected to enroll approximately 100 patients with advanced solid tumors or non-Hodgkin lymphoma.
  • Kronos Bio leverages its SMM screening platform to conduct high-throughput screens against traditionally undruggable target proteins, in particular transcription factors.
  • The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.